Numero speciale di "Impact Factor News” n° 6 - Settembre 2026
Heerspink HJL, et al. Lancet 2026; 407: 2387–2401
Atrasentan in patients with IgA nephropathy (ALIGN): final 2.5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial
